(Q51024001)

27 March 2018

title

Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. (English)

1 reference

27 March 2018

1 reference

3

Irene Andrulis

1 reference

27 March 2018

Rosemary E Mueller

1

1 reference

27 March 2018

Robert K Parkes

series ordinal

2

1 reference

27 March 2018

Frances P O'Malley

series ordinal

4

1 reference

27 March 2018

publication date

1 April 2004

1 reference

27 March 2018

Genes, Chromosomes and Cancer

published in

1 reference

27 March 2018

volume

39

1 reference

27 March 2018

issue

4

1 reference

27 March 2018

page(s)

288-297

1 reference

27 March 2018

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

cites work

1 reference

Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor

21 January 2018

1 reference

Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme

21 January 2018

1 reference

Physiological regulation of eukaryotic topoisomerase II

21 January 2018

1 reference

Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation

21 January 2018

1 reference

7 January 2021

Optimum anthracycline-based chemotherapy for early breast cancer

1 reference

7 January 2021

Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens

1 reference

7 January 2021

Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions

1 reference

7 January 2021

Ki67 protein: the immaculate deception?

1 reference

7 January 2021

Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions

1 reference

7 January 2021

Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections

1 reference

7 January 2021

Ras stimulates DNA topoisomerase II alpha through MEK: a link between oncogenic signaling and a therapeutic target

1 reference

7 January 2021

Translational control by an upstream open reading frame in the HER-2/neu transcript

1 reference

7 January 2021

Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum

1 reference

7 January 2021

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

1 reference

7 January 2021

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

1 reference

7 January 2021

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

7 January 2021

Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3'-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation.

1 reference

7 January 2021

Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells

1 reference

7 January 2021

Molecular analysis of chromosome arm 17q gain in neuroblastoma

1 reference

7 January 2021

Effects of HER-2/neu on chemosensitivity of tumor cells

1 reference

7 January 2021

Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20

1 reference

7 January 2021

Culprit and victim -- DNA topoisomerase II.

1 reference

7 January 2021

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

7 January 2021

Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells

1 reference

7 January 2021

Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer

1 reference

7 January 2021

Generalized Linear Models

1 reference

7 January 2021

High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas.

1 reference

7 January 2021

DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates

1 reference

7 January 2021

Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ

1 reference

7 January 2021

Evidence for the use of chemotherapy in breast cancer

1 reference

7 January 2021

DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer

1 reference

7 January 2021

Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry

1 reference

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

7 January 2021

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

7 January 2021

AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen

1 reference

7 January 2021

Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors

1 reference

7 January 2021

Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer

1 reference

7 January 2021

p53 regulates the minimal promoter of the human topoisomerase IIalpha gene

1 reference

7 January 2021

Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value

1 reference

7 January 2021

Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity

1 reference

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

7 January 2021

Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network

1 reference

7 January 2021

Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression

1 reference

7 January 2021

Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas

1 reference

7 January 2021

Cellular roles of dna topoisomerases: a molecular perspective

1 reference

7 January 2021

Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate

1 reference

7 January 2021

Untangling the ErbB signalling network

1 reference

7 January 2021

Identifiers

DOI

10.1002/GCC.20008

1 reference

27 March 2018

1 reference

27 March 2018